Six articles, in full.

SQL Server 2014 reached the end of extended support on July 9, 2024. Extended Security Updates have covered it since, and the third and final ESU year began on July 15, 2026 and ends on July 12, 2027. There is no fourth year. If you are still running SQL Server 2014, you are inside the last twelve months of security coverage that will ever exist for it.

The Full Timeline

From Microsoft's lifecycle page for SQL Server 2014:

• Released: June 5, 2014

• Mainstream support ended: July 9, 2019

• Extended support ended: July 9, 2024

• ESU Year 1: July 10, 2024 to July 8, 2025

• ESU Year 2: July 9, 2025 to July 14, 2026

• ESU Year 3, the final year: July 15, 2026 to July 12, 2027

Service Pack 3, released October 30, 2018, was the last service pack and was supported to the same July 9, 2024 date.

The One Advantage SQL Server 2014 Still Has

This is the part worth knowing, because it disappears with the next version and most write-ups have not caught up.

SQL Server 2014 customers receive Extended Security Updates at no additional cost by migrating workloads to Azure. Microsoft confirms free ESUs for SQL Server 2014 on SQL Server on Azure Virtual Machines, on Azure VMware Solution virtual machines, and on Azure Stack. You can even deploy a brand new SQL Server 2014 instance on an Azure VM and have access to free ESUs until availability ends.

SQL Server 2016 customers get none of that. Microsoft explicitly ended free Azure ESUs starting with SQL Server 2016, stating that migrating your workload to SQL Server on Azure VMs no longer provides free access to ESUs. On Azure Stack, 2014 ESUs are free and 2016 ESUs must be purchased.

So the lift-and-shift-to-Azure play still works, and it works only for 2014 and earlier. If you have SQL Server 2014 instances that genuinely cannot be upgraded before July 2027, moving them to an Azure virtual machine as-is is worth costing out against the paid on-premises route. The free coverage still expires in July 2027 either way.

Who Qualifies for ESU

Only the Enterprise and Standard editions of SQL Server 2014 are eligible, for both x86 and x64. Express, Web, Business Intelligence, and Developer editions cannot be covered. Organizations holding ESUs for production workloads may apply those updates to Developer edition instances, but solely for development and test purposes.

Outside Azure, qualification requires active Software Assurance under an Enterprise Agreement, Enterprise Agreement Subscription, Server and Cloud Enrollment, or Enrollment for Education Solutions. Alternatively you can connect instances to Azure Arc and use pay-as-you-go billing, which provides ESUs without Software Assurance. Connecting instances to Azure Arc is free.

Service Pack 3 Is a Hard Prerequisite

You must be running Service Pack 3 to apply ESUs, because Microsoft only produces updates that install on the latest service pack. An instance sitting on SP2 cannot take an ESU patch at all.

There is a second prerequisite worth acting on before you need it. ESUs released for SQL Server 2014 include the most recent cumulative update. Microsoft advises that if you only ever applied General Distribution Release updates during the normal support period, you should install and validate the latest cumulative update at the time you subscribe rather than waiting for the first ESU to arrive. Otherwise an urgent security patch will fail to install because it carries a CU you have never tested, at the worst possible moment.

What the Updates Actually Are

SQL Server ESUs include only security updates rated Critical by the Microsoft Security Response Center. Windows Server ESUs cover Critical and Important; SQL Server does not. Microsoft's explanation is that SQL Server does not ship a general monthly security update and only produces on-demand updates where MSRC identifies SQL Server as an affected product.

There is therefore no release cadence. Updates arrive if and when a qualifying vulnerability is found, and in many months there will not be one. Do not interpret a quiet month as a coverage failure.

What an Unpatched Database Engine Actually Attracts

It is worth being precise about the risk rather than dramatic. A database server is rarely the initial point of compromise, because it is usually not directly internet-facing. What it is, reliably, is the highest-value target inside the perimeter, and the thing an attacker moves towards after gaining a foothold elsewhere.

That shapes the practical consequence of running unpatched. The exposure is not that someone scans the internet and finds your SQL Server. It is that a compromise which should have been contained to one segment becomes a data breach, because the database engine in the path had a known, published, permanently unpatched vulnerability. Unpatched database engines are what turn incidents into disclosures.

What to Do Before July 2027

You are in the final ESU year, so the decision set has narrowed to three options. Upgrade to a supported SQL Server release, which is the default answer. Migrate to Azure SQL Managed Instance, which removes the lifecycle question permanently rather than resetting it. Or, for instances that genuinely cannot move in time, confirm your ESU coverage is active through July 12, 2027 and use that year to finish the migration rather than to defer it again.

The one thing that does not work is planning for a fourth ESU year. The program is capped at three by design, that cap has never been extended for a SQL Server release, and July 12, 2027 is the last day a security update for SQL Server 2014 exists.

References

1. Microsoft. "SQL Server 2014 - Microsoft Lifecycle." https://learn.microsoft.com/en-us/lifecycle/products/sql-server-2014

2. Microsoft. "Extended Security Updates FAQ - SQL Server." https://learn.microsoft.com/en-us/sql/sql-server/end-of-support/extended-security-updates-frequently-asked-questions

3. Microsoft. "What Are Extended Security Updates? - SQL Server." https://learn.microsoft.com/en-us/sql/sql-server/end-of-support/sql-server-extended-security-updates

4. Microsoft. "Product Lifecycle FAQ - Extended Security Updates." https://learn.microsoft.com/en-us/lifecycle/faq/extended-security-updates

Timothy Francis Leary (October 22, 1920 – May 31, 1996) began his career as a respected clinical psychologist and ended it as one of the most recognizable, and most polarizing, figures of the American counterculture. Over three and a half decades he moved from academic personality research at Harvard to public advocacy of LSD and psilocybin, then through prison, escape, and exile, and finally into a late-life role as an early enthusiast of computers and virtual reality. President Richard Nixon reportedly called him "the most dangerous man in America," while poet Allen Ginsberg described him as a hero of American consciousness. Few figures capture the promise and excess of the 1960s psychedelic movement as fully as Leary does.

Early Life and Education

Leary was born in Springfield, Massachusetts, the only child of an Irish Catholic family. His father, a dentist, left the family when Leary was a teenager. His path through higher education was unsettled: he attended the College of the Holy Cross, then transferred under family pressure to the United States Military Academy at West Point, where he was accused of an honor-code violation, refused to resign, and was acquitted at court-martial but shunned by fellow cadets for the rest of his time there. He eventually left West Point, finished his undergraduate degree at the University of Alabama in 1943, earned a master's degree in psychology at Washington State College, and completed a PhD in clinical psychology at the University of California, Berkeley in 1950. His doctoral dissertation treated group therapy as a kind of measurable system, an early version of the ideas that would define his academic reputation.

From Clinical Psychologist to Psychedelic Researcher

Through the 1950s, Leary built a conventional academic career. He worked as an assistant clinical professor at the University of California, San Francisco and helped found the psychology department at Kaiser Hospital in Oakland. In 1957 he published The Interpersonal Diagnosis of Personality, which introduced what is now known as the interpersonal circumplex, a model for mapping personality traits along interconnected axes. The book was well received in professional circles and later influenced the popular field of transactional analysis, including Eric Berne's Games People Play and Thomas Harris's I'm OK, You're OK. This period of Leary's life was also marked by personal tragedy: his first wife, Marianne, died by suicide in 1955, leaving him to raise their two children alone.

In 1959, at the invitation of colleagues from Berkeley, Leary joined Harvard University as a lecturer in clinical psychology. The turning point in his life came the following year. In August 1960, on a trip to Cuernavaca, Mexico, Leary ate psilocybin mushrooms for the first time. He later said the experience taught him more about psychology in five hours than he had learned in the previous fifteen years of academic study.

The Harvard Psilocybin Project

Back at Harvard, Leary and a younger colleague, Richard Alpert, launched the Harvard Psilocybin Project to study the drug's effects on human subjects. Their most cited studies were the Concord Prison Experiment, which explored whether guided psilocybin sessions could reduce reoffending among released prisoners, and the Marsh Chapel Experiment, which examined whether psilocybin could reliably produce genuine religious experiences in seminary students. Both projects reported striking results, though later researchers challenged their scientific rigor.

The project drew growing scrutiny. Colleagues objected that Leary and Alpert took the drugs alongside their subjects, that they pressured students to participate, and that they gave psychedelics to undergraduates in violation of university policy. Coverage in the student newspaper, the Harvard Crimson, brought the controversy into public view. In May 1963, Harvard dismissed Alpert for giving psilocybin to an undergraduate off campus, and dismissed Leary as well, officially for missing scheduled lectures, though the drug controversy was widely understood to be the real cause. LSD and psilocybin were still legal in the United States at the time.

Millbrook and the Rise of a Movement

After Harvard, Leary and Alpert continued their work outside the university, first through the International Federation for Internal Freedom, then through a communal group based at a 64-room estate in Millbrook, New York, donated by heirs to the Mellon fortune. Millbrook became the operational and spiritual center of Leary's psychedelic circle for roughly five years, hosting continuous LSD sessions alongside meditation and yoga retreats, while also drawing repeated raids from local law enforcement.

In 1964, Leary, Alpert, and Ralph Metzner published The Psychedelic Experience, a guide to LSD sessions modeled on the Tibetan Book of the Dead. In 1966, Leary reorganized his following as the League for Spiritual Discovery, a religious organization built around LSD as a sacrament, partly as a legal strategy to protect psychedelic use under freedom-of-religion arguments. That same year, Leary testified before a Senate subcommittee chaired by Thomas Dodd, arguing against criminalizing psychedelics and instead proposing a licensing system for adult users. The argument failed to persuade lawmakers: California banned LSD in October 1966, and it became illegal nationwide by 1968.

"Turn On, Tune In, Drop Out"

On January 14, 1967, Leary addressed roughly 30,000 people at the Human Be-In in San Francisco's Golden Gate Park and delivered the phrase that would define his public image: "turn on, tune in, drop out." Leary later said the slogan originated in a conversation with media theorist Marshall McLuhan, who suggested he needed "something snappy" to promote psychedelics. Leary's own, more detailed explanation of the phrase framed it as a three-part discipline: detaching from conventional social patterns, finding a personal practice that reconnected the individual to their own body and mind, and then returning to ordinary life changed by the experience. In practice, the slogan was absorbed by the wider counterculture as a simple call to drop conventional ambitions and expand consciousness through drugs, and it became one of the most quoted lines of the decade.

Arrests, Prison Escape, and Exile

Leary's public profile made him a repeated target for law enforcement; he was arrested roughly three dozen times over his life. His first serious case came in December 1965, when a small amount of marijuana was found on his daughter at the US-Mexico border. He was convicted under the Marihuana Tax Act and sentenced to 30 years, a sentence the Supreme Court later overturned in 1969 on the grounds that the law violated the Fifth Amendment right against self-incrimination. On the day of that ruling, Leary announced a campaign for governor of California against Ronald Reagan; John Lennon, whom Leary had met that year, wrote the song "Come Together" based on Leary's campaign slogan.

A second marijuana arrest in 1968 led to a ten-year sentence in January 1970, later combined with an earlier sentence for a total of twenty years. Assigned to a low-security prison after psychological testing that Leary, drawing on tests he had designed himself, deliberately gamed, he escaped over a fence in September 1970 with help from the radical Weather Underground. He and his wife Rosemary Woodruff fled the country, eventually reaching Algeria, where Black Panther leader Eldridge Cleaver initially sheltered them and later placed them under house arrest. The couple then moved to Switzerland, where an arms dealer offered them protection in exchange for film rights to Leary's story, and Swiss authorities briefly jailed but refused to extradite him despite pressure from the Nixon administration. Leary was finally detained in Afghanistan in 1972 by US federal agents and returned to the United States, where he was sent to Folsom Prison, at one point housed in a cell next to Charles Manson. He was released in 1976 after cooperating with FBI investigators, an episode that damaged his standing with former allies including Ginsberg and his own son.

Later Years: From Psychedelics to Cyberdelics

After his release, Leary settled in the Laurel Canyon neighborhood of Los Angeles and rebuilt a public career as an author and lecturer, at times billing himself a "stand-up philosopher." He toured with his former nemesis G. Gordon Liddy, the Watergate figure who had once led drug raids on Millbrook, in a series of debates that drew large audiences. During the 1980s, Leary largely stepped back from openly promoting drug use and instead became a prominent advocate for space colonization, life extension, and eventually personal computing, declaring that "the PC is the LSD of the 1990s." He befriended early virtual-reality pioneers, demonstrated emerging technology at his talks, and served as a consultant on Billy Idol's 1993 album Cyberpunk, becoming an unlikely bridge figure between 1960s psychedelic culture and 1990s digital culture.

Death

Diagnosed with inoperable prostate cancer in 1995, Leary approached his illness as he had approached much of his life: publicly and unconventionally, calling it "designer dying" and updating a website with details of his declining health in what amounted to an early blog. He explored the possibility of cryonic preservation before ultimately deciding against it, and he had his death filmed at his request. He died at his Beverly Hills home on May 31, 1996, at age 75. A portion of his cremated remains was later launched into orbit aboard a rocket alongside those of Star Trek creator Gene Roddenberry and other public figures, as part of a private space-burial company's mission.

Effect on Psychedelic Culture

Leary's influence on the 1960s counterculture is difficult to overstate. His slogans gave the psychedelic movement a public language, his Harvard credentials gave LSD advocacy an early veneer of scientific legitimacy, and his very public conflicts with the government helped make him a symbol of the era's clash between establishment authority and youth rebellion. His work with the Tibetan Book of the Dead shaped how a generation of musicians and artists thought about psychedelic experience, most famously inspiring the Beatles' song "Tomorrow Never Knows." At the same time, mainstream psychology and psychiatry largely distanced themselves from his research methods, and critics both inside and outside academia argued that his enthusiasm outran his evidence.

His legacy is correspondingly mixed. Supporters credit him with opening a serious conversation about the therapeutic potential of psychedelics, a conversation that has resurfaced in the clinical "psychedelic renaissance" of the 21st century, including renewed research at Harvard itself. Critics point to the ethical problems in his original studies, his sometimes reckless public claims about psychedelics' safety, and the personal toll his lifestyle took on people around him, including family members. Nearly three decades after his death, Leary remains a reference point whenever the history of psychedelic drugs, 1960s counterculture, or the boundaries between science and advocacy come up for discussion.

References

1. Wikipedia contributors. "Timothy Leary." Wikipedia, The Free Encyclopedia. en.wikipedia.org/wiki/Timothy_Leary

2. Wikipedia contributors. "Harvard Psilocybin Project." Wikipedia, The Free Encyclopedia. en.wikipedia.org/wiki/Harvard_Psilocybin_Project

3. Wikipedia contributors. "Turn on, tune in, drop out." Wikipedia, The Free Encyclopedia. en.wikipedia.org/wiki/Turn_on,_tune_in,_drop_out

4. Encyclopaedia Britannica. "Timothy Leary." britannica.com/biography/Timothy-Leary

5. Harvard University, Department of Psychology. "Timothy Leary (1920–1996)." psychology.fas.harvard.edu/people/timothy-leary

6. Hiatt, Nathaniel J. "A Trip Down Memory Lane: LSD at Harvard." The Harvard Crimson, May 23, 2016. thecrimson.com/article/2016/5/23/trip-down-memory-lane/

7. "LSD Guru Leary Dies at 75." The Harvard Crimson, June 3, 1996. thecrimson.com/article/1996/6/3/lsd-guru-leary-dies-at-75/

8. VICE. "Timothy Leary Turns 100: America's LSD Messiah, Remembered By Those Who Knew Him." October 23, 2020. vice.com/en/article/timothy-leary-lsd-acid-history/

9. The Washington Post. "The Ultimate Trip of Timothy Leary." June 1, 1996. washingtonpost.com/archive/lifestyle/1996/06/01/the-ultimate-trip-of-timothy-leary/18b3d0f7-fdb2-4ceb-ac26-b087bb88e68f/

10. Baltimore Sun. "'60s psychedelia guru Timothy Leary, 75, dies." baltimoresun.com/1996/06/01/60s-psychedelia-guru-timothy-leary-75-dies-lsd-advocate-tapped-into-information-age/

11. NPR. "Father Of The Psychedelic Movement, Timothy Leary." Fresh Air, October 21, 2020. npr.org/2020/10/21/926181349/father-of-the-psychedelic-movement-timothy-leary

12. New York Public Library. "Timothy Leary Papers, 1910–2009" (finding aid). archives.nypl.org/mss/18400

13. Psychedelic Science Review. "Timothy Leary." psychedelicreview.com/person/timothy-leary/

14. Wikimedia Commons. "Category:Timothy Leary" (image sources). commons.wikimedia.org/wiki/Category:Timothy_Leary

For nearly four decades, a modest house in Lafayette, California, a Bay Area town most people couldn't place on a map, served as an unlikely epicenter of psychedelic science. The property, known to those who passed through it simply as "the Farm," was home to a chemist and a self-taught therapist whose combined work would shape how the world understood, feared, criminalized, and eventually began to medicalize psychedelic drugs. Alexander "Sasha" Shulgin synthesized and tested more psychoactive compounds than perhaps anyone in history. His wife, Ann, brought the psychological framework that gave that chemistry meaning. Together they didn't just discover molecules — they built a philosophy, a literature, and eventually a movement around them.

The making of a chemist

Sasha Shulgin was born June 17, 1925, in Berkeley, California, to two schoolteachers. He was an academically gifted teenager, admitted to Harvard at sixteen on a full scholarship. But he never felt at home there, surrounded by classmates from wealth and social standing he didn't share. He dropped out after less than two years and joined the Navy, serving in the North Atlantic during World War II. After his discharge in 1946, he returned to California and enrolled at UC Berkeley, eventually earning a Ph.D. in biochemistry in 1954, followed by postdoctoral work in psychiatry and pharmacology at UC San Francisco.

His entry into industrial chemistry came at Dow Chemical, where he developed Zectran, one of the first biodegradable pesticides. It was a genuine commercial win for Dow, and the company rewarded him with something rare: freedom. Given wide discretion over what to research next, Shulgin chose psychedelics — a decision set in motion a few years earlier, in 1960, when he tried mescaline with friends. The experience surfaced long-buried memories and feelings, and left him fixated on a simple, startling idea: that a fraction of a gram of a white solid could unlock an entire hidden architecture of the mind.

By the mid-1960s, that fixation had outgrown what a corporate lab could accommodate. Shulgin left Dow in 1966 and set up an independent laboratory on his own property, continuing his work as a private consultant, including, for years, as an occasional contractor and expert witness for the very federal agency that would later end his run: the DEA. Because his research required legal access to Schedule I substances, he held a DEA license permitting him to handle and analyze controlled compounds. It was an unusual arrangement that let a lone chemist, working mostly out of a home lab, operate at the edge of both legitimate pharmacology and the underground drug culture developing around him.

Rediscovering MDMA

Contrary to popular shorthand, Shulgin did not invent MDMA. The compound was first synthesized by the German pharmaceutical company Merck in 1912, filed away as an intermediate with no evidence anyone tested it on a human being. Shulgin himself first made MDMA in 1965, but set it aside without trying it. It wasn't until the mid-1970s, after hearing about an unusual "special effect" attributed to the molecule, that he resynthesized it and, in September 1976, tried it himself — an experience his own lab notes describe in unusually rapturous terms, as a kind of homecoming.

What happened next mattered more than the chemistry itself. In 1977, Shulgin introduced MDMA to Leo Zeff, a psychotherapist who became convinced of its potential as a tool for opening up patients in therapy. Zeff spent the following years quietly training and supplying hundreds of other therapists, and for a time MDMA circulated almost entirely within careful clinical settings — known to insiders by names like "Adam" or simply "empathy," years before the wider public would ever hear the word Ecstasy. Historians of the drug generally credit Shulgin not as MDMA's inventor, but as the person most responsible for recognizing its psychological significance and setting its therapeutic use in motion — which is why he's often, if imprecisely, called its "father."

MDMA was only the beginning. Over the following decades, working largely from that home laboratory, Shulgin discovered, synthesized, and personally bioassayed more than two hundred psychoactive compounds, most from two chemical families: the phenethylamines — including the well-known "2C" series such as 2C-B, 2C-E, 2C-I, 2C-T-2, and 2C-T-7 — and, later, a wide range of tryptamines. To bring some rigor to what was otherwise a deeply subjective undertaking, he developed a standardized method for rating a compound's effects and intensity, now known as the Shulgin Rating Scale — a framework still referenced in both clinical literature and the informal drug-testing culture that grew up online in the decades since.

The therapist behind the science

Ann Shulgin's path to Lafayette was less linear. Born Laura Ann Gotlieb on March 22, 1931, in Wellington, New Zealand, the daughter of an American diplomat, she spent her childhood moving between Italy, Texas, Cuba, and Canada before eventually studying art in California. By the time she met Sasha in 1978, she had been married and divorced three times and had worked for years as a medical transcriber while raising her children. She and Sasha married in 1981.

Ann was never a licensed psychotherapist, and she never pretended otherwise — she referred to herself plainly as a "lay therapist." But she brought a serious grounding in Jungian psychology to the couple's work, with a particular focus on what Jung called the Shadow: the parts of the self a person represses, denies, or is too afraid to face directly. She came to believe that certain psychoactive compounds, used carefully and with intention, could help dissolve the defenses that normally keep those parts of the psyche walled off. In the years before MDMA and 2C-B were made illegal, she worked directly with people in therapeutic sessions built around that belief, and she wrote some of the earliest practical guidelines for using MDMA safely within a therapeutic context — a foundational document for a field that wouldn't have institutional legitimacy again for another thirty years.

The division of labor between the two of them became something of a running line in their own household: he was the scientist, she was the psychologist. It was a partnership in the fullest sense — Sasha synthesizing and characterizing new molecules, Ann interpreting what those molecules did to the human mind, and both of them hosting a rotating cast of scientists, therapists, students, and psychonauts who made pilgrimages to the Farm over the decades.

PiHKAL, TiHKAL, and a collision with the DEA

In 1991, the Shulgins published PiHKAL: A Chemical Love Story — an acronym for "Phenethylamines I Have Known and Loved." It's a strange and genuinely unclassifiable book: half of it is a fictionalized memoir of their courtship and marriage, narrated through characters named Shura and Alice; the other half is a dense technical catalogue describing roughly two hundred compounds, along with detailed accounts of their subjective effects. A companion volume, TiHKAL: The Continuation, followed in 1997, covering tryptamines in the same dual format. Together, the books fused hard chemistry, autobiography, and philosophy in a way no one else had attempted, and they became foundational texts for an entire generation of underground chemists, researchers, and psychedelic explorers.

That publication came at a cost. In 1994, two years after PiHKAL appeared — reportedly prompted by an interview the couple had given to High Times — the DEA raided the Farm. Agents cited record-keeping violations and asked Shulgin to surrender the license that had let him legally handle Schedule I materials; he was also fined $25,000 for possessing analytical samples that had been sent to him for testing outside proper channels. It was a notable reversal: two earlier DEA inquiries, in 1986 and 1992, had turned up nothing. After consulting a lawyer, the Shulgins decided not to fight the license revocation, calculating that a legal battle would be costly and unlikely to succeed. Sasha kept working anyway, simply operating within the narrower legal bounds that remained open to him.

From the therapy room to the dance floor

The years after Shulgin introduced MDMA to Leo Zeff trace almost exactly the arc that would come to define — and endanger — the drug's reputation. What began as a tightly controlled clinical tool used by therapists moved, by the mid-1980s, into recreational nightlife, first in American clubs and then, memorably, in Ibiza and the broader European rave scene, where it became inseparable from the emerging culture of all-night electronic dance music. As MDMA's popularity spread far beyond the therapy rooms where it had started, so did uncontrolled manufacturing, adulterated pills, and a wave of overdose deaths tied to impurities, dosage, and overheating — problems that had far more to do with unregulated street chemistry than with the drug Shulgin had studied. In 1985, the DEA placed MDMA into Schedule I, the most restrictive category under U.S. law, over objections from researchers and even from a federal administrative law judge who had recommended the far less restrictive Schedule III.

That criminalization effectively ended the first era of MDMA-assisted psychotherapy for nearly three decades. But it didn't end the culture the Shulgins had helped create. PiHKAL and TiHKAL kept circulating — legally protected in the U.S. by the First Amendment, illegal to even possess in a number of other countries — and their published MDMA synthesis reportedly remains, to this day, one of the routes most commonly encountered in illicit manufacturing. The books also pushed regulators to tighten control over legal chemical precursors like safrole, a direct response to compounds documented in PiHKAL turning up in clandestine labs around the world.

A legacy that outlived them

Sasha Shulgin died on June 2, 2014, at the Farm, at the age of 88, following years of declining health after a stroke. Ann died eight years later, on July 9, 2022, at the same home, at 91, after living with chronic obstructive pulmonary disease. The Farm remains tied to their memory: friends, researchers, and former students held Ann's memorial in Berkeley's Zellerbach Hall the following year, and the Shulgin Foundation now works to preserve their papers, their home, and their approach to psychedelic research and education.

That approach — rigorous, self-experimental chemistry paired with careful psychological interpretation — is now widely cited as a direct forerunner of what researchers call the "psychedelic renaissance": the resurgence of serious clinical interest in MDMA, psilocybin, and related compounds at institutions like Johns Hopkins and Imperial College London. The clearest thread runs straight back to Sasha's own molecule. Decades after he handed MDMA to Leo Zeff, the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies) — and later its associated company, Lykos Therapeutics — spent over twenty years building the clinical case for MDMA-assisted therapy as a treatment for PTSD, culminating in a New Drug Application submitted to the FDA in December 2023. The agency granted it priority review in early 2024, a genuine milestone as the first such application for any psychedelic-assisted therapy. But in August 2024, the FDA issued a Complete Response Letter declining to approve it, citing concerns about trial design and asking for an additional Phase 3 study. Lykos has since had further discussions with the FDA about a path forward, and the question of whether MDMA will ultimately win approval as a mental-health treatment remains open.

Whatever the outcome of that regulatory fight, the Shulgins' fingerprints are already permanent. Sasha gave the world — and its underground chemists alike — a working vocabulary and methodology for an entire class of understudied molecules. Ann gave that chemistry a psychological frame that treated altered consciousness as material for genuine self-understanding rather than mere escape. Between the two of them, working out of a house in the Bay Area suburbs, they turned a private hobby into a discipline serious enough that, half a century later, the FDA is still deciding what to do about it.

References

1. Multidisciplinary Association for Psychedelic Studies (MAPS). "Alexander Shulgin, Chemist Behind MDMA, Dies at 88." maps.org/news/media/alexander-shulgin-chemist-behind-mdma-dies-at-88/

2. Wikipedia contributors. "Alexander Shulgin." Wikipedia, The Free Encyclopedia. en.wikipedia.org/wiki/Alexander_Shulgin

3. Benzenhöfer, U. and Passie, T. "Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin." Addiction, 2010. pubmed.ncbi.nlm.nih.gov/20653618/

4. Chemical & Engineering News (C&EN). "Alexander T. (Sasha) Shulgin." cen.acs.org/articles/92/i33/Alexander-T-Sasha-Shulgin.html

5. The Washington Post (via Nalle Winery reprint). "Chemist Alexander Shulgin, popularizer of MDMA, dies at 88." nallewinery.com/blog/chemist-alexander-shulgin-popularizer-of-mdma-says-his-favorite-mind-altering-drug-is-a-nice-moderately-expensive-zinfandel/

6. The Boston Globe. "Ann Shulgin, pioneer of psychedelics in therapy, dies at 91." July 13, 2022. bostonglobe.com/2022/07/13/metro/ann-shulgin-pioneer-psychedelics-therapy-dies-91/

7. CBS News San Francisco. "Ann Shulgin, pioneer of psychedelics in therapy, dies at 91 in Lafayette home." cbsnews.com/sanfrancisco/news/ann-shulgin-pioneer-of-psychedelics-in-therapy-dies/

8. The Shulgin Foundation. "About the Shulgins." shulginfoundation.org/about-the-shulgins/

9. Purdue University Archives and Special Collections. "Shulgin, Ann" (biographical note). archives.lib.purdue.edu/agents/people/3653

10. PsychonautWiki. "Alexander Shulgin." psychonautwiki.org/wiki/Alexander_Shulgin

11. MuckRock. "The DEA raided 'the grandfather of ecstasy' over a High Times article." June 23, 2016. muckrock.com/news/archives/2016/jun/23/shulgin-dea/

12. Erowid. "1994 Raid of Shulgin Lab." erowid.org/culture/characters/shulgin_alexander/shulgin_alexander_raid.shtml

13. mdma.net. "Alexander Shulgin and 2C-T-7 (and PIHKAL, TIHKAL and the DEA)." mdma.net/alexander-shulgin/2c-t-7.html

14. Reality Sandwich. "Alexander Shulgin: Pioneering the Psychedelic Renaissance." realitysandwich.com/alexander-shulgin-legacy/

15. MAPS. "Molecules Have No Morals: Ecstasy Godfather Alexander Shulgin's Legacy." maps.org/news/media/molecules-have-no-morals-ecstasy-godfather-alexander-shulgins-legacy/

16. MAPS. "MAPS Statement on FDA's Public Release of Complete Response Letter for MDMA-assisted Therapy." September 4, 2025. maps.org/2025/09/04/fda-public-release-of-crl/

17. Psychedelic Support. "FDA's Decision: Why Lykos' MDMA for PTSD NDA Was Rejected." psychedelic.support/resources/fda-decision-lykos-ptsd-mdma-nda-rejected/

18. Fierce Biotech. "Lykos accepts FDA view that MDMA approval relies on fresh trial." fiercebiotech.com/biotech/lykos-accepts-fdas-view-reviving-mdma-treatnents-fortunes-requires-fresh-trial